{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:40:12Z","timestamp":1790973612899,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smoldering multiple myeloma (SMM) to overt MM. There are large racial disparities in all stages of the disease. Compared with Whites, Blacks have an increased MGUS and MM risk and higher mortality rate, and have not experienced the same survival gains over time. The roots of this disparity are likely multifactorial in nature. Comparisons of Black and White MGUS and MM patients suggest that differences in risk factors, biology, and clinical characteristics exist by race or ancestry, which may explain some of the observed disparity in MM. However, poor accrual of Black MGUS and MM patients in clinical and epidemiological studies has limited our understanding of this disparity and hindered its elimination. Disparities in MM survival also exist but appear to stem from inferior treatment utilization and access rather than underlying pathogenesis. Innovative and multidisciplinary approaches are urgently needed to enhance our understanding of disparities that exist at each stage of the MM disease continuum and facilitate their elimination.<\/jats:p>","DOI":"10.1038\/s41408-020-0284-7","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:16:06Z","timestamp":1581959766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Dissecting racial disparities in multiple myeloma"],"prefix":"10.1038","volume":"10","author":[{"given":"Catherine R.","family":"Marinac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Birmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Rebbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"284_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood. 111, 2962\u20132972 (2008).","journal-title":"Blood."},{"key":"284_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"284_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4, 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"key":"284_CR4","unstructured":"Howlader, N. et al. SEER Cancer Statistics Review, 1975-2012. (National Cancer Institute, Bethesda, MD, 2015)."},{"key":"284_CR5","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 113, 5418\u20135422 (2009).","journal-title":"Blood."},{"key":"284_CR6","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 113, 5412\u20135417 (2009).","journal-title":"Blood."},{"key":"284_CR7","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"284_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"284_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 106, 812\u2013817 (2005).","journal-title":"Blood."},{"key":"284_CR10","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"284_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1022268103136","volume":"22","author":"M Benjamin","year":"2003","unstructured":"Benjamin, M., Reddy, S. & Brawley, O. W. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 22, 87\u201393 (2003).","journal-title":"Cancer Metastasis Rev."},{"key":"284_CR12","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman, A. J. et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 116, 5501\u20135506 (2010).","journal-title":"Blood."},{"key":"284_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10552-006-0030-x","volume":"17","author":"M Gebregziabher","year":"2006","unstructured":"Gebregziabher, M., Bernstein, L., Wang, Y. & Cozen, W. Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States). Cancer Causes Control 17, 931\u2013938 (2006).","journal-title":"Cancer Causes Control"},{"key":"284_CR14","unstructured":"National Cancer Institute. SEER*Explorer: an Interactive Website for SEER Cancer Statistics [Internet]. Surveillance Research Program (National Cancer Institute, 2019). [Cited 15 Apr 2019]. Available from https:\/\/seer.cancer.gov\/explorer\/."},{"key":"284_CR15","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","volume":"116","author":"O Landgren","year":"2010","unstructured":"Landgren, O. et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 116, 1056\u20131059 (2010).","journal-title":"Blood."},{"key":"284_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","volume":"107","author":"O Landgren","year":"2006","unstructured":"Landgren, O. et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 107, 904\u2013906 (2006).","journal-title":"Blood."},{"key":"284_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren, O. et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 7, e618 (2017).","journal-title":"Blood Cancer J."},{"key":"284_CR18","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","volume":"82","author":"O Landgren","year":"2007","unstructured":"Landgren, O. et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin. Proc. 82, 1468\u20131473 (2007).","journal-title":"Mayo Clin. Proc."},{"key":"284_CR19","doi-asserted-by":"publisher","first-page":"2819372","DOI":"10.1155\/2017\/2819372","volume":"2017","author":"GK Singh","year":"2017","unstructured":"Singh, G. K. & Jemal, A. Socioeconomic and racial\/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J. Environ. Public Health. 2017, 2819372 (2017).","journal-title":"J. Environ. Public Health."},{"key":"284_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05339.x","volume":"1186","author":"DR Williams","year":"2010","unstructured":"Williams, D. R., Mohammed, S. A., Leavell, J. & Collins, C. Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. Ann. N Y Acad. Sci. 1186, 69\u2013101 (2010).","journal-title":"Ann. N Y Acad. Sci."},{"key":"284_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2105\/AJPH.90.8.1277","volume":"90","author":"D Baris","year":"2000","unstructured":"Baris, D. et al. Socioeconomic status and multiple myeloma among US blacks and whites. Am. J. Public Health. 90, 1277\u20131281 (2000).","journal-title":"Am. J. Public Health."},{"key":"284_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","volume":"114","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 114, 791\u2013795 (2009).","journal-title":"Blood."},{"key":"284_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","volume":"114","author":"CM Vachon","year":"2009","unstructured":"Vachon, C. M. et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114, 785\u2013790 (2009).","journal-title":"Blood."},{"key":"284_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ajh.21325","volume":"84","author":"M Jain","year":"2009","unstructured":"Jain, M., Ascensao, J. & Schechter, G. P. Familial myeloma and monoclonal gammopathy: a report of eight African American families. Am. J. Hematol. 84, 34\u201338 (2009).","journal-title":"Am. J. Hematol."},{"key":"284_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa0708704","volume":"359","author":"HT Lynch","year":"2008","unstructured":"Lynch, H. T. et al. Familial myeloma. N. Engl. J. Med. 359, 152\u2013157 (2008).","journal-title":"N. Engl. J. Med."},{"key":"284_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10552-015-0685-2","volume":"27","author":"ME VanValkenburg","year":"2016","unstructured":"VanValkenburg, M. E. et al. Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control 27, 81\u201391 (2016).","journal-title":"Cancer Causes Control"},{"key":"284_CR27","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2385::AID-CNCR13>3.0.CO;2-A","volume":"85","author":"LM Brown","year":"1999","unstructured":"Brown, L. M. et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer. 85, 2385\u20132390 (1999).","journal-title":"Cancer."},{"key":"284_CR28","unstructured":"Du, Z. et al. A meta-analysis of genome-wide association studies of multiple myeloma in persons of african ancestry [African-American Multiple Myeloma Study (AAMMS)] identifies suggestive risk variants. Blood 130, 3058 (2017)."},{"key":"284_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41416-018-0010-4","volume":"118","author":"CR Marinac","year":"2018","unstructured":"Marinac, C. R. et al. Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Br. J. Cancer. 118, 1013\u20131019 (2018).","journal-title":"Br. J. Cancer."},{"key":"284_CR30","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","volume":"26","author":"BM Birmann","year":"2017","unstructured":"Birmann, B. M. et al. Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC). Cancer Epidemiol. Biomarkers Prev. 26, 876\u201385. (2017).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"284_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.gtc.2016.07.012","volume":"45","author":"C Arroyo-Johnson","year":"2016","unstructured":"Arroyo-Johnson, C. & Mincey, K. D. Obesity epidemiology worldwide. Gastroenterol. Clin. North Am. 45, 571\u2013579 (2016).","journal-title":"Gastroenterol. Clin. North Am."},{"key":"284_CR32","unstructured":"Ogden, C. L., Carroll, M. D., Fryar, C. D. & Flegal, K. M. Prevalence of obesity among adults and youth: United States, 2011\u20132014. NCHS Data Brief. 219, 1\u20138 (2015)."},{"key":"284_CR33","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1001\/archinte.165.18.2098","volume":"165","author":"RP Hertz","year":"2005","unstructured":"Hertz, R. P., Unger, A. N., Cornell, J. A. & Saunders, E. Racial disparities in hypertension prevalence, awareness, and management. Archiv. Int. Med. 165, 2098\u20132104 (2005).","journal-title":"Archiv. Int. Med."},{"key":"284_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2337\/diaclin.30.3.130","volume":"30","author":"EA Chow","year":"2012","unstructured":"Chow, E. A., Foster, H., Gonzalez, V. & McIver, L. The disparate impact of diabetes on racial\/ethnic minority populations. Clin. Diabetes. 30, 130\u2013133 (2012).","journal-title":"Clin. Diabetes."},{"key":"284_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/ERC-15-0029","volume":"22","author":"R Rios","year":"2015","unstructured":"Rios, R. et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr. Relat. Cancer. 22, 545\u2013559 (2015).","journal-title":"Endocr. Relat. Cancer."},{"issue":"5","key":"284_CR36","doi-asserted-by":"publisher","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","volume":"109","author":"Su-Hsin Chang","year":"2016","unstructured":"Chang, S. H. et al. Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study. J. Natl Cancer Inst. 109, djw264 (2017).","journal-title":"Journal of the National Cancer Institute"},{"key":"284_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir, E. E. et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 1, 168\u2013174 (2015).","journal-title":"JAMA Oncol."},{"key":"284_CR38","first-page":"666","volume":"94","author":"A Nelson","year":"2002","unstructured":"Nelson, A. Unequal treatment: confronting racial and ethnic disparities in health care. J. Natl Med. Assoc. 94, 666\u2013668 (2002).","journal-title":"J. Natl Med. Assoc."},{"key":"284_CR39","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/cncr.29160","volume":"121","author":"V Bhatnagar","year":"2015","unstructured":"Bhatnagar, V. et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer. 121, 1064\u20131070 (2015).","journal-title":"Cancer."},{"key":"284_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/jnci\/djp175","volume":"101","author":"KS Albain","year":"2009","unstructured":"Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A. Jr. & Hershman, D. L. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J. Natl Cancer Inst. 101, 984\u2013992 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"284_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0102-7","volume":"8","author":"S Ailawadhi","year":"2018","unstructured":"Ailawadhi, S. et al. Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 8, 67 (2018).","journal-title":"Blood Cancer J."},{"key":"284_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/bloodadvances.2017010512","volume":"2","author":"ED Pulte","year":"2018","unstructured":"Pulte, E. D. et al. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2, 116\u2013119 (2018).","journal-title":"Blood Adv."},{"key":"284_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.91","volume":"5","author":"AJ Greenberg","year":"2015","unstructured":"Greenberg, A. J. et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J. 5, e271 (2015).","journal-title":"Blood Cancer J."},{"key":"284_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng, W. J. et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 28, 269\u2013277 (2014).","journal-title":"Leukemia."},{"key":"284_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","volume":"9","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian, D. et al. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer J. 9, 15 (2019).","journal-title":"Blood Cancer J."},{"key":"284_CR46","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca, R. et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 101, 4569\u20134575 (2003).","journal-title":"Blood."},{"key":"284_CR47","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","volume":"100","author":"P Moreau","year":"2002","unstructured":"Moreau, P. et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 100, 1579\u20131583 (2002).","journal-title":"Blood."},{"key":"284_CR48","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca, R. et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 99, 3735\u20133741 (2002).","journal-title":"Blood."},{"key":"284_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","volume":"8","author":"LB Baughn","year":"2018","unstructured":"Baughn, L. B. et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 8, 96 (2018).","journal-title":"Blood Cancer J."},{"key":"284_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3109\/10428194.2013.827188","volume":"55","author":"D Pulte","year":"2014","unstructured":"Pulte, D., Redaniel, M. T., Brenner, H., Jansen, L. & Jeffreys, M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk. Lymphoma. 55, 1083\u20131089 (2014).","journal-title":"Leuk. Lymphoma."},{"key":"284_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"LJ Costa","year":"2017","unstructured":"Costa, L. J. et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 1, 282\u2013287 (2017).","journal-title":"Blood Adv."},{"key":"284_CR52","doi-asserted-by":"crossref","unstructured":"Winn, A. N., Shah, G. L., Cohen, J. T., Lin, P. J., & Parsons S. K. The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J. Natl Cancer Inst. 107, djv139 (2015).","DOI":"10.1093\/jnci\/djv139"},{"key":"284_CR53","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","volume":"21","author":"LJ Costa","year":"2015","unstructured":"Costa, L. J., Huang, J. X. & Hari, P. N. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol. Blood Marrow Transplant. 21, 701\u2013706 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"284_CR54","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/cncr.30526","volume":"123","author":"MA Fiala","year":"2017","unstructured":"Fiala, M. A. & Wildes, T. M. Racial disparities in treatment use for multiple myeloma. Cancer. 123, 1590\u20131596 (2017).","journal-title":"Cancer."},{"key":"284_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bbmt.2009.11.007","volume":"16","author":"PN Hari","year":"2010","unstructured":"Hari, P. N. et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 16, 395\u2013402 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"284_CR56","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","volume":"21","author":"DP Scharff","year":"2010","unstructured":"Scharff, D. P. et al. More than Tuskegee: understanding mistrust about research participation. J. Health Care Poor Underserved. 21, 879\u2013897 (2010).","journal-title":"J. Health Care Poor Underserved."},{"key":"284_CR57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11899-017-0393-y","volume":"12","author":"S Ailawadhi","year":"2017","unstructured":"Ailawadhi, S., Bhatia, K., Aulakh, S., Meghji, Z. & Chanan-Khan, A. Equal treatment and outcomes for everyone with multiple myeloma: are we there yet? Curr. Hematol. Malig. Rep. 12, 309\u201316. (2017).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"284_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","volume":"15","author":"RS Go","year":"2015","unstructured":"Go, R. S., Gundrum, J. D. & Neuner, J. M. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin. Lymphoma Myeloma Leuk. 15, 177\u2013186 e4 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"284_CR59","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde, N. et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 1, 746\u2013754 (2015).","journal-title":"JAMA Oncol."},{"key":"284_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.23159","volume":"87","author":"T Golombick","year":"2012","unstructured":"Golombick, T., Diamond, T. H., Manoharan, A. & Ramakrishna, R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am. J. Hematol. 87, 455\u2013460 (2012).","journal-title":"Am. J. Hematol."},{"key":"284_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"284_CR62","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","volume":"117","author":"N Korde","year":"2011","unstructured":"Korde, N., Kristinsson, S. Y. & Landgren, O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 117, 5573\u20135581 (2011).","journal-title":"Blood."},{"key":"284_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"284_CR64","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2012-07-443606","volume":"121","author":"A Baker","year":"2013","unstructured":"Baker, A. et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 121, 3147\u20133152 (2013).","journal-title":"Blood."},{"key":"284_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007087","volume":"13","author":"Z Manojlovic","year":"2017","unstructured":"Manojlovic, Z. et al. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet. 13, e1007087 (2017).","journal-title":"PLoS Genet."},{"key":"284_CR66","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ajh.22025","volume":"86","author":"BM Weiss","year":"2011","unstructured":"Weiss, B. M. et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. Am. J. Hematol. 86, 475\u2013478 (2011).","journal-title":"Am. J. Hematol."},{"key":"284_CR67","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/leu.2009.134","volume":"23","author":"O Landgren","year":"2009","unstructured":"Landgren, O. & Weiss, B. M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis. Leukemia. 23, 1691\u20131697 (2009).","journal-title":"Leukemia."},{"key":"284_CR68","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10900-017-0339-2","volume":"42","author":"LB Adams","year":"2017","unstructured":"Adams, L. B., Richmond, J., Corbie-Smith, G. & Powell, W. Medical mistrust and colorectal cancer screening among African Americans. J. Community Health. 42, 1044\u20131061 (2017).","journal-title":"J. Community Health."},{"key":"284_CR69","doi-asserted-by":"crossref","unstructured":"Altrock, P. M., Ferlic, J., Galla, T., Tomasson, M. H. & Michor, F. Computational model of progression to multiple myeloma identifies optimum screening strategies. JCO Clin. Cancer Inform. 2, 1\u201312 (2018).","DOI":"10.1200\/CCI.17.00131"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0284-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:25:27Z","timestamp":1670250327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0284-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0284-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M.G. has the following potential conflicts of interest to disclose: honoraria: Celgene, Bristol-Myers Squibb, Takeda, Amgen; consulting or advisory role: Bristol-Myers Squibb, Novartis, Amgen, Takeda, Celgene, Cellectar, Sanofi; travel, accommodations, expenses: Bristol-Myers Squibb, Novartis, Celgene, Takeda, Janssen Oncology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"19"}}